YD Bio (YDES) Assets (2024 - 2025)
YD Bio's (YDES) quarterly Assets came in at $13.8 million in Q4 2025, up 100.74% year-on-year from $6.9 million in Q4 2024, and up 135.9% on a QoQ basis from $5.8 million in Q2 2025.
YD Bio (YDES) Assets (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Assets data on file, last reported at $13.8 million in Q4 2025.
- On a quarterly basis, Assets rose 100.74% year-over-year to $13.8 million in Q4 2025; TTM through Dec 2025 was $13.8 million, a 100.74% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, up 100.74% from the prior year.
- Assets for Q4 2025 stood at $13.8 million, up from $5.8 million in the prior quarter.
- Over the last five years, Assets for YDES reached as high as $13.8 million in Q4 2025 and fell as low as $5.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.25 Bn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 13.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.78 Mn |
| Jun 30, 2025 | 5.84 Mn |
| Dec 31, 2024 | 6.86 Mn |